TAIPEI, Dec. 26, 2024 /PRNewswire/ — VIVOTEK (3454-TW), the global leading security solution provider, has once again demonstrated its outstanding commitment to sustainability. Participating for the first time in the 17th Taiwan Corporate Sustainability Awards (TCSA), VIVOTEK emerged victorious, earning the Sustainability Report Award for the Information, Communication, and Broadcasting Industry and the Taiwan Corporate Sustainability Excellence Award. These recognitions showcase VIVOTEK’s remarkable success in corporate governance, environmental protection, and social responsibility, affirming its dedication to sustainable growth.

Pioneering Sustainability with Dual Recognition

“For over seven years, VIVOTEK has independently published sustainability reports, actively driving and disclosing our internal sustainability initiatives.” said Allen Hsieh, VIVOTEK’s Spokesperson and Director of the Global Marketing Division. “These awards not only recognize our integrity and efforts in presenting operational performance, environmental data, and social impact but also serve as a strong motivation for us to continue advancing on the path of sustainable development.”

Driving Sustainability through AI Innovation

VIVOTEK delivers advanced AI-powered security solutions built on cutting-edge AI and edge computing technologies. Beyond innovation, the company drives green initiatives, reduces its carbon footprint, and fosters a sustainable, supportive workplace.

Committed to social responsibility, VIVOTEK leads the security industry’s sustainability efforts through its ‘Safety Map’ initiative. For four years, employees have formed security teams to enhance safety in neighborhoods, care centers, and schools with on-site assessments and improvement plans.

In 2024, VIVOTEK will expand its efforts to Hualien’s Dacheng Village, where it will help improve local safety environments and support cultural preservation and tourism revitalization. These actions reflect its dedication to sustainability, community well-being, and lasting societal contributions.

Security Sustainability as a Foundation for Social Impact

VIVOTEK proudly received two prestigious honors at the Taiwan Corporate Sustainability Awards, highlighting its dedication to sustainable practices. These accolades inspire the company to deepen its internal efforts and mark the start of an exciting new chapter.

Building on this achievement, VIVOTEK aims to strengthen its mission of becoming the world’s most trusted smart security brand. By aligning with global market needs and fostering collaboration with customers, partners, and employees, VIVOTEK is committed to shaping a sustainable future founded on mutual trust and shared success.

To learn more about VIVOTEK’s sustainability initiatives, please refer to the 2023 Sustainability Report.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vivotek-wins-double-honors-for-its-commitment-to-sustainability-302339206.html

SOURCE VIVOTEK Inc.

BEIJING, Dec. 26, 2024 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WiMi) (“WiMi” or the “Company”), a leading global Hologram Augmented Reality (“AR”) Technology provider, today announced the development of a Quantum Technology-Based Random Access Memory Architecture, known as QRAM. This architecture successfully implements fundamental logical operations such as AND, OR, NOT, and NOR gates in quantum logic gates by combining key basic operations in quantum computing, such as the CNOT gate, V gate, and V+ gate. Quantum Random Access Memory (QRAM) is a memory architecture specifically designed for quantum computing environments, with the core goal of enabling efficient reading and writing of information while maintaining the state of the quantum system. The design of QRAM is not only intended to leverage the parallel processing capabilities of quantum computing but also to utilize quantum properties such as superposition and entanglement to significantly enhance computational efficiency.

In WiMi’s QRAM architecture, the quantum CNOT gate, V gate, and V+ gate serve as the fundamental operation units. Each quantum operation is equivalent to certain logical operations in classical computing, but simultaneously leverages the properties of quantum states to achieve efficient computation.

CNOT Gate (Controlled-NOT Gate): The CNOT gate is a crucial operation in quantum computing, used to control the relationship between two quantum bits (qubits). In classical computing, this is similar to the function of an XOR gate, but in the quantum environment, it allows qubits to exist in a superposition of states, enabling the simultaneous processing of multiple states.

V Gate and V+ Gate: The V gate and V+ gate are quantum gates used to implement more complex logic. The operations of these two gates are similar to the AND and OR gates in classical computing. However, their advantage lies in the ability to process multiple potential outcomes in the quantum system simultaneously, without the need to evaluate each possibility separately.

By combining these fundamental quantum gates, basic operations in quantum logic such as AND, OR, NOT, and NOR can be successfully implemented. This provides the necessary support for designing complex quantum circuits, while being more flexible and efficient compared to classical logic gates.

One of the major advantages of the QRAM architecture is its full utilization of the properties of quantum superposition and quantum entanglement. In classical computing, memory read and write operations are linear and must be performed sequentially. However, in quantum computing, because qubits can exist in multiple states (superposition), parallel read and write operations can be performed simultaneously. This ability significantly enhances computational efficiency, especially when handling large-scale datasets or complex computational tasks.

Additionally, quantum entanglement enables the correlation between multiple qubits without the need for direct communication, further improving the speed of data transfer and computation. Memory operations with entangled qubits are much faster and more efficient than traditional memory operations, opening up new possibilities for parallel computing.

In WiMi’s QRAM architecture, the entire design logic includes several key steps and technical nodes, such as quantum state-based random access, the introduction of quantum error correction mechanisms, and seamless integration with quantum computers.

The core feature of QRAM is its ability to perform random access within a quantum system. Traditional computer RAM achieves reading and writing to memory units through address buses, data buses, and other components, whereas QRAM accomplishes this process through the states of quantum bits (qubits). By utilizing quantum superposition, multiple addresses can be accessed simultaneously in a single operation. This means that in a QRAM system, data can be accessed in parallel across multiple addresses, greatly improving the efficiency of data operations.

To achieve this, WiMi has designed a system based on CNOT gates, V gates, and V+ gates. These quantum gates allow flexible control over memory access processes while maintaining the quantum state of the system and ensuring the efficient transmission of qubits in an entangled state. Through this system, QRAM not only enables high-speed data reading and writing, but also ensures the reliability and accuracy of information processing.

Furthermore, error correction is crucial in any quantum computing system. Due to the fragile nature of qubit states, even small external disturbances can cause computational errors. Therefore, WiMi’s QRAM architecture incorporates a quantum error correction mechanism to ensure that the qubit states are accurately preserved and transmitted during data reading and writing. This includes an error correction method based on quantum entanglement, where redundant entangled qubits are introduced to detect and correct potential errors. This method not only effectively reduces the impact of external noise on the system but also ensures the stability of data during multiple read operations.

WiMi’s QRAM design is intended to seamlessly integrate with quantum computers. Since quantum computing operations depend on the superposition and entanglement states of qubits, the QRAM system demonstrates high compatibility when interfacing with a quantum processing unit (QPU). The design ensures smooth transmission of qubits between memory and processor during data access, thereby significantly improving computational efficiency.

By utilizing the V gate, V+ gate, and CNOT gate, WiMi’s QRAM system can quickly execute quantum logic operations and, when handling complex computational tasks, can read and write data at near-real-time speeds. This makes QRAM a key component in large-scale quantum computing applications.

The successful development of QRAM technology has had a revolutionary impact across multiple fields. As a critical component of quantum computers, QRAM will significantly enhance the overall performance of quantum computing systems. Its efficient parallel data access capabilities make it especially well-suited for handling large-scale computational tasks such as molecular simulations, climate modeling, and complex optimization problems. By significantly reducing computation time, QRAM will play an indispensable role in the future of high-performance quantum computing.

Another important application of QRAM is in quantum communication and quantum encryption. By leveraging quantum entanglement, QRAM can enable high-speed data transmission while ensuring data security. The non-locality of quantum entanglement guarantees that data cannot be intercepted during transmission, providing a solid foundation for future quantum encryption technologies.

With the development of quantum computing, the field of quantum machine learning has also gradually emerged. QRAM’s efficient data access capabilities make it highly suitable for handling large-scale datasets, enabling model training to be completed in a shorter time. This will significantly advance the development of quantum artificial intelligence, allowing complex machine learning tasks to be solved quickly on quantum computers.

As quantum technology continues to evolve, QRAM, as a core technology, will provide crucial support for the future of quantum computing. WiMi is committed to continuing the development of QRAM technology, continually optimizing its performance, reducing implementation costs, and expanding its applications across various industries.

The successful development of QRAM technology marks an important step in the advancement of quantum computing. As quantum computers progress and quantum technologies mature, QRAM will become an indispensable core component of quantum computing systems. With the ongoing optimization and promotion of this technology, QRAM is expected to bring disruptive innovations across multiple fields and lay a solid foundation for the arrival of the quantum era.

About WiMi Hologram Cloud

WiMi Hologram Cloud, Inc. (NASDAQ:WiMi) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.

Safe Harbor Statements

This press release contains “forward-looking statements” within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company’s strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission (“SEC”) on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services.

Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.

View original content:https://www.prnewswire.com/news-releases/wimi-develops-a-quantum-technology-based-random-access-memory-architecture-302339317.html

SOURCE WiMi Hologram Cloud Inc.

USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Dec. 26, 2024 /CNW/ — USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system’s power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively targeting cancer cells while preserving healthy tissue. These innovations underscore the relentless pursuit of breakthroughs in oncology to enhance patient outcomes. Among the key players driving recent progress in the field are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Erasca, Inc. (NASDAQ: ERAS), Allogene Therapeutics, Inc. (NASDAQ: ALLO), Context Therapeutics Inc. (NASDAQ: CNTX), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).

The article continued: The oncology field continues to advance, with MarketsAndMarkets forecasting the Artificial Intelligence in Oncology Market to reach $11.52 billion by 2030, driven by a 29.4% CAGR. Similarly, Nova Advisor predicts the Personalized Cell Therapy Market will grow at a 23.53% CAGR, reaching $251.37 billion by 2034.

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, recently released a recap of major accomplishments from 2024 and a preview of anticipated milestones for the next 12 months. Following the promising BRACELET-1 readout, Oncolytics expects additional data readouts across its clinical development program in 2025, forming what it believes is a clear pathway to future commercialization opportunities.

“This past year produced highly encouraging clinical developments that we believe set the stage for significant progress, headlined by the robust efficacy results from the BRACELET-1 breast cancer study,” said Wayne Pisano, Interim CEO and Chair of Oncolytics Biotech’s Board of Directors. “In addition, our gastrointestinal cancer program continues to impress, resulting in meaningful collaborations with well-respected experts in the field. Key opinion leaders in both breast and GI cancers continue to be excited by pelareorep’s potential as we move into 2025. Based on these insights from leading oncologists, we believe pelareorep has the potential to become a transformational immunotherapy—and that pelareorep-based combination therapies could accelerate our path toward regulatory approval. We are very optimistic about our plans for the next year, and we look forward to showcasing our latest clinical progress early in the new year at the ASCO GI Symposium—an event that could provide key catalysts for our ongoing gastrointestinal cancer programs. Unlike many immunotherapies that struggle to convert ‘cold’ tumors to ‘hot,’ pelareorep’s unique mechanism of action following intravenous delivery has shown the potential to significantly boost patients’ immune responses—making previously unresponsive tumors more susceptible to treatment. I would like to say thank you to our shareholders, clinical collaborators, study sites and their staff, the patients who participate in our trials, and the employees of Oncolytics Biotech who have stepped up in a significant way in the temporary absence of our CEO, Matt Coffey.”

Oncolytics Biotech continues to advance pelareorep, its innovative immunotherapy for multiple cancer indications. Final efficacy results from the BRACELET-1 study in HR+/HER2- metastatic breast cancer demonstrated a median overall survival benefit exceeding one year and a two-year survival rate nearly double that of paclitaxel monotherapy. These findings, supported by earlier IND-213 data, further reinforce pelareorep’s transformative potential. With FDA alignment on a planned registration-enabling study, Oncolytics Biotech aims to offer improved treatment options for approximately 55,000 U.S. patients annually.

Significant progress has also been made in pancreatic cancer, with plans for a registration-enabling study supported by collaborations with the Global Coalition for Adaptive Research (GCAR) and Roche. This follows the GOBLET study’s outcomes, which more than doubled response rates in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. Additionally, the PanCAN-funded GOBLET cohort evaluating pelareorep plus mFOLFIRINOX, with or without atezolizumab, has completed safety run-in enrollment, receiving positive feedback from the Data Safety Monitoring Board. Key findings from this cohort, alongside progress in anal cancer, will be presented at the ASCO GI Symposium in January 2025.

Looking ahead, Oncolytics Biotech will present at the Biotech Showcase on January 13, 2025, and host investor meetings during the J.P. Morgan Healthcare Conference that same week. These events will provide a platform to highlight its clinical advancements and reinforce its commitment to addressing critical unmet needs in oncology.

CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/

In other recent industry developments and happenings in the market include:

Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, recently provided updates on its R&D advancements targeting RAS/MAPK pathway-driven cancers. In October 2024, the company presented promising Phase 1b SEACRAFT-1 data for naporafenib plus trametinib (MEKINIST®), showing potential for an NRAS-mutated melanoma indication and supporting the ongoing Phase 3 SEACRAFT-2 trial. Erasca also announced progress on its pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 programs, confirming best-in-class potential and preparing for IND submissions in 2025. Key milestones include data from SEACRAFT-2 in 2025 and initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 in 2026.

“We made significant progress across our pipeline programs and are pleased with the pace of our execution,” said Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca. “Positive preliminary data from SEACRAFT-1, which we reported at the 36th EORTC-NCI-AACR (ENA) Symposium last month, has refined our clinical development focus of naporafenib plus trametinib on patients with NRAS-mutant (NRASm) melanoma, and importantly, heightens our conviction in the ongoing SEACRAFT-2 registrational trial targeting a similar patient population. SEACRAFT-2 has the potential for approval based on the high unmet need of these patients as well as the alignment with US and European regulators on the NRASm melanoma indication. We expect randomized dose optimization data from Stage 1 of this Phase 3 trial in 2025.”

Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology company, recently announced new data from the Phase 1 TRAVERSE trial evaluating ALLO-316, its first AlloCAR T™ product candidate, for advanced or metastatic renal cell carcinoma (RCC). Presented at the 2024 IKCS and SITC Annual Meetings, the data demonstrated a 50% overall response rate (ORR) and a 33% confirmed response rate (CRR) in patients with CD70 Tumor Proportion Scores (TPS) ≥50%. ALLO-316 showed robust CAR T cell expansion, manageable safety, and durable tumor responses, supporting the FDA’s RMAT designation for advanced RCC. Additional data from the ongoing Phase 1b expansion cohort is expected in mid-2025.

“ALLO-316, the leading “off-the-shelf” CAR T product candidate currently in development for solid tumors, continues to show remarkable potency in the TRAVERSE trial,” said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer of Allogene. “Data from the Phase 1 study demonstrating significant anti-tumor activity in patients with metastatic disease resistant to multiple therapeutic classes, even with standard lymphodepletion, potentially marks a major advancement in the field. The unprecedented cell expansion and persistence driven by CD70 CAR-intrinsic Dagger® technology, along with strong evidence of tumor infiltration by CAR T cells, highlights the distinctive features of ALLO-316. We believe these findings from our Phase 1 trial lay the groundwork for a new generation of allogeneic cell therapies.”

Context Therapeutics Inc. (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, recently announced advancements in its T cell-engaging bispecific antibody pipeline, including CT-202, a Nectin-4 x CD3 antibody licensed in September 2024, with an IND filing expected in mid-2026. Context also acquired CT-95, a Mesothelin x CD3 antibody, set to begin Phase 1 trials in Q1 2025. Additionally, Context will present data on its Claudin 6-targeting antibody CTIM-76 at the SITC Annual Meeting.

“Context executed on its strategy to build a pipeline of T cell engaging bispecific antibodies through its acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody,” said Martin Lehr, CEO of Context. “We continue to activate additional sites for our Phase 1 trial for CTIM-76, a Claudin 6 x CD3 bispecific antibody, and expect to dose our first patient by the end of this year. We also expect to advance CT-95 into the clinic soon and expect to enroll our first patient in our CT-95 Phase 1 study in the first quarter of 2025.”

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical stage TechBio company, recently announced interim data from the Phase 1/2 ELUCIDATE trial of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The trial showed REC-617 was well-tolerated with no discontinuations due to adverse events, and one patient with platinum-resistant ovarian cancer achieved a confirmed partial response lasting over six months, while four others had stable disease for up to six months. With plans to continue dose escalation and initiate combination studies in early 2025, REC-617 demonstrates potential as a safe and effective therapy in heavily pre-treated cancer patients.

“Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive cancers,” said David Hallett, Ph.D., Chief Scientific Officer of Recursion. “By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level.”

Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

CONTACT:

USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.com/news-releases/oncology-in-focus-how-emerging-therapies-are-reshaping-cancer-treatment-302339333.html

SOURCE USA News Group